Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034916.xml
Download PDF
Nervenheilkunde 2005; 24(01): 41-47
DOI: 10.1055/s-0038-1629932
DOI: 10.1055/s-0038-1629932
Original Article
Affektive Symptome beim Morbus Parkinson und atypischen Parkinson-Syndromen
Affective symptoms in idiopathic Parkinson’s disease and atypical Parkinsonian syndromesFurther Information
Publication History
Eingegangen am:
15 October 2004
angenommen nach Revision am:
03 November 2004
Publication Date:
30 January 2018 (online)
Zusammenfassung
Die Depression ist ein häufiges Symptom bei idiopathischen und atypischen Parkinson-Syndromen und beeinflusst neben den Aktivitäten des täglichen Lebens auch wesentlich die Lebensqualität der Betroffenen. Die Studienlage belegt, wie schwierig es ist, die affektiven Symptome zu messen und sie effizient zu behandeln. Für das idiopathische Parkinson-Syndrom liegen Untersuchungen zur Wirksamkeit einer antidepressiven Pharmakotherapie vor, allerdings erfüllen sie gegenwärtig noch nicht die Kriterien der evidenzbasierten Medizin. Für die atypischen Parkinson-Syndrome (Multisystematrophie, progressive supranukleäre Blickparese, Demenz mit Lewy-Körperchen und kortikobasale Degeneration) bestehen bislang erst klinische Fallsammlungen. Die Wahl der antidepressiven Therapie bei idiopathischen und atypischen Parkinson-Syndromen ist daher eine individuelle Entscheidung und beruht auf der Kenntnis der aktuell verfügbaren Literatur, die im Folgenden zusammengefasst wird.
Summary
Parkinson’s disease and atypical Parkinsonian syndromes are neurological disorders with prominent depressive symptoms. Assessment and treatment of depression are important to improve the activities of daily living and the quality of life of the patients. The efficacy of antidepressant treatment in Parkinson’s disease has not been convincingly established yet. The use of antidepressants in atypical Parkinsonian syndromes (multiple system atrophy, progressive supranuclear palsy, Lewy body dementia and corticobasal degeneration) has been reported in single-case studies. This article provides updates on depressive symptoms in these disorders.
-
Literatur
- 1 Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-6.
- 2 Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 42-9.
- 3 Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17: 164-71.
- 4 Allain H, Schuck S, Mauduit N. Depression in Parkinson’s disease. BMJ 2000; 320: 1287-8.
- 5 Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta Neurol Scand 1980; 62: 210-9.
- 6 Anderson KE, Weiner WJ. Psychiatric symptoms in Parkinson’s disease. Curr Neurol Neurosci Rep 2002; 2: 303-9.
- 7 Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry R. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry 1999; 156: 1039-45.
- 8 Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, Nagy Z, Perry EK, Joachim C, Jaros E, O’Brien JT, Perry RH, McKeith IG. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry 2004; 161: 843-9.
- 9 Brandstadter D, Oertel WH. Depression in Parkinson’s disease. Adv Neurol 2003; 91: 371-81.
- 10 Brown R, Jahanshahi M. Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61-84.
- 11 Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 1988; 18: 49-55.
- 12 Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord 2002; 17: 445-54.
- 13 Burn DJ. Depression in Parkinson’s disease. Eur J Neurol 2002; 9 (Suppl. 03) 44-54.
- 14 Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson’s disease. Ann Neurol 1992; 32 (Suppl): S125-7.
- 15 Cannas A, Spissu A, Floris GL, Congia S, Saddi MV, Melis M, Mascia MM, Pinna F, Tuveri A, Solla P, Milia A, Giagheddu M, Tacconi P. Bipolar affective disorder and Parkinson’s disease: a rare, insidious and often unrecognized association. Neurol Sci 2002; 23 (Suppl. 02) S67-8.
- 16 Ceballos-Baumann A, Lemke MR. Parkinson-Syndrom und Depression. Nervenheilkunde 2004; 23: 143-150.
- 17 Ceravolo R, Nuti A, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, Dell’Osso L, Murri L, Bonuccelli U. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000; 55: 1216-8.
- 18 Charlton CG. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that may explain the occurrence of depression in Parkinson’s disease. Life Sci 1997; 61: 495-502.
- 19 Chiu HF. Psychiatric aspects of progressive supranuclear palsy. Gen Hosp Psychiatry 1995; 17: 135-43.
- 20 Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE. Systematic review of antidepressant therapies in Parkinson’s disease. Parkinsonism Relat Disord 2003; 10: 59-65.
- 21 Cubo E, Rojo A, Ramos S, Quintana S, Gonzalez M, Kompoliti K, Aguilar M. The importance of educational and psychological factors in Parkinson’s disease quality of life. Eur J Neurol 2002; 9: 589-93.
- 22 Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443-54.
- 23 Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50: 873-80.
- 24 Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48: S10-6.
- 25 Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. Adv Neurol 2000; 82: 147-52.
- 26 Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. In: Cummings JL, Litvan I. (eds.). Corticobasal degeneration. Advances in Neurology. Philadelphia: Lippincott Williams & Wilkins; 2000: 147-52.
- 27 Cummings JL, Masterman DL. Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatry 1999; 14: 711-8.
- 28 Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999; 122 (Pt 8): 1437-48.
- 29 Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24: 221-7.
- 30 Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003; 60: 601-5.
- 31 Duffy J, Coffey C. The neurobiology of depression. In: Timble M, Cummings J. (eds.). Contemporary behavioral neurology. Oxford: Butterwort Heinemann; 1997: 275-89.
- 32 Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990; 3: 3-9.
- 33 Esmonde T, Giles E, Gibson M, Hodges JR. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. J Neurol 1996; 243: 638-43.
- 34 Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991; 114 (Pt 5): 2283-301.
- 35 Fetoni V, Soliveri P, Monza D, Testa D, Girotti F. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999; 66: 541-4.
- 36 Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26: 142-5.
- 37 Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381-9.
- 38 Goto K, Ueki A, Shimode H, Shinjo H, Miwa C, Morita Y. Depression in multiple systematrophy: a case report. Psychiatry Clin Neurosci 2000; 54: 507-11.
- 39 Green AR, Sant K, Bowdler JM, Cowen PJ. Further evidence for a relationship between changes in GABA concentration in rat brain and enhanced monoamine-mediated behavioural responses following repeated electroconvulsive shock. Neuropharmacology 1982; 21: 981-4.
- 40 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1967; 23: 56-62.
- 41 Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997; 12: 756-9.
- 42 Hooten WM, Melin G, Richardson JW. Response of the Parkinsonian symptoms of multiple system atrophy to ECT. Am J Psychiatry 1998; 155: 1628.
- 43 Janati A, Appel AR. Psychiatric aspects of progressive supranuclear palsy. J Nerv Ment Dis 1984; 172: 85-9.
- 44 Jellinger K. Overview of morphological changes in Parkinson’s disease. Adv Neurol 1987; 45: 1-18.
- 45 Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J Affect Disord 1983; 5: 141-5.
- 46 Kim E, Zwil AS, McAllister TW, Glosser DS, Stern M, Hurtig H. Treatment of organic bipolar mood disorders in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1994; 6: 181-4.
- 47 Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag HM. Treatment of depression in Parkinson’s disease: a metaanalysis. J Neuropsychiatry Clin Neurosci 1995; 7: 281-6.
- 48 Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 1996; 47: 1148-52.
- 49 Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson’s disease. Mov Disord 2000; 15: 216-23.
- 50 Laitinen L. Desipramine in treatment of Parkinson’s disease. A placebo-controlled study. Acta Neurol Scand 1969; 45: 109-13.
- 51 Lane RM. SSRI-induced extrapyramidal sideeffects and akathisia: implications for treatment. J Psychopharmacol 1998; 12: 192-214.
- 52 Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson’s disease: epidemiology and management. CNS Drugs 2001; 15: 267-75.
- 53 Leentjens AF. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17: 120-6.
- 54 Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson’s disease. Acta Psychiatr Scand 2002; 106: 196-201.
- 55 Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15: 74-7.
- 56 Leentjens AF, van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 2003; 18: 414-8.
- 57 Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry 2000; 15: 644-9.
- 58 Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry 2003; 18: 552-4.
- 59 Lemke MR. Effect of reboxetine on depression in Parkinson’s disease patients. J Clin Psychiatry 2002; 63: 300-4.
- 60 Lemke MR. Reboxetine treatment of depression in Parkinson’s disease. J Clin Psychiatry 2000; 61: 872.
- 61 Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65: 717-21.
- 62 Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47: 1184-9.
- 63 MacDonald AW, 3rd Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000; 288: 1835-8.
- 64 Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 1995; 45: 1757-60.
- 65 Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer’s disease. Neurology 1996; 46: 720-6.
- 66 Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner Jr HN, Robinson RG. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 1990; 28: 57-64.
- 67 McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 2003; 54: 363-75.
- 68 McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, doubleblind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
- 69 McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
- 70 McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: 911-22.
- 71 Meara J, Hobson P. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1998; 13: 622.
- 72 Menza MA, Cocchiola J, Golbe LI. Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics 1995; 36: 550-4.
- 73 Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12: 49-52.
- 74 Migliorelli R, Starkstein SE, Teson A, de Quiros G, Vazquez S, Leiguarda R, Robinson RG. SPECT findings in patients with primary mania. J Neuropsychiatry Clin Neurosci 1993; 5: 379-83.
- 75 Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O’Connor MK, Black JL, Pileggi T. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10: 187-93.
- 76 Montastruc JL, Fabre N, Blin O, Senard JM, Rascol O, Rascol A. Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 1995; 10: 355-7.
- 77 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
- 78 Naarding P, Leentjens AF, van Kooten F, Verhey FR. Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer’s dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002; 14: 329-34.
- 79 Netzel PJ, Sutor B. Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy. J Ect 2001; 17: 68-70.
- 80 Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 2002; 106: 202-11.
- 81 Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the ›on-off‹ phenomenon in Parkinson’s disease. Psychol Med 1987; 17: 899-904.
- 82 Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30: 263-5.
- 83 Okun MS, Watts RL. Depression associated with Parkinson’s disease: clinical features and treatment. Neurology 2002; 58: S63-70.
- 84 Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56: S1-S88.
- 85 Perkin GD, Lees AJ, Stern GM, Kocen RS. Problems in the diagnosis of progressive supranuclear palsy (Steele Richardson Olszewski syndrome). Can J Neurol Sci 1978; 5: 168-73.
- 86 Pilo L, Ring H, Quinn N, Trimble M. Depression in multiple system atrophy and in idiopathic Parkinson’s disease: a pilot comparative study. Biol Psychiatry 1996; 39: 803-7.
- 87 Poewe W, Luginger E. Depression in Parkinson’s disease: impediments to recognition and treatment options. Neurology 1999; 52: S2-6.
- 88 Poewe W, Wenning GK. Atypische Parkinson-Sydrome. In: Brandt T, Dichgans J, Diener H. (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer 2003; 265-82.
- 89 Rasmussen Jr KG, Russell JC, Kung S, Rummans TA, Rae-Stuart E, O’Connor MK. Electroconvulsive therapy for patients with major depression and probable Lewy body dementia. J Ect 2003; 19: 103-9.
- 90 Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J, Klajblova H, Kulist’ak P, Ressner P, Svatova J, Urbanek K, Veliskova J. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406.
- 91 Rey GJ, Tomer R, Levin BE, Sanchez-Ramos J, Bowen B, Bruce JH. Psychiatric symptoms, atypical dementia, and left visual field inattention in corticobasal ganglionic degeneration. Mov Disord 1995; 10: 106-10.
- 92 Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 48: 1070-7.
- 93 Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ. Depression in Parkinson’s disease. A positron emission study. Br J Psychiatry 1994; 165: 333-9.
- 93 Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117 (Pt 5): 1183-96.
- 94 Roane DM, Rogers JD, Helew L, Zarate J. Electroconvulsive therapy for elderly patients with multiple system atrophy: a case series. Am J Geriatr Psychiatry 2000; 8: 171-4.
- 95 Ruxin RJ, Ruedrich S. ECT in combined multiple system atrophy and major depression. Convuls Ther 1994; 10: 298-300.
- 96 Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004; 363: 1783-93.
- 97 Samuels SC, Brickman AM, Burd JA, Purohit DP, Qureshi PQ, Serby M. Depression in autopsy-confirmed dementia with Lewy bodies and Alzheimer’s disease. Mt Sinai J Med 2004; 71: 55-62.
- 98 Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-3.
- 99 Schneider LS, Chui HC. Progressive supranuclear palsy manifesting with depressive features. J Am Geriatr Soc 1986; 34: 663-5.
- 100 Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-8.
- 101 Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease?. Psychol Med 2001; 31: 65-73.
- 102 Shabnam GN, Chung T, Deane KH, Rickards H, Clarke CE. Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003; CD003465.
- 103 Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000; 15: 669-77.
- 104 Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 193-7.
- 105 Simard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000; 12: 425-50.
- 106 Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG. Depression in patients with early versus late onset of Parkinson’s disease. Neurology 1989; 39: 1441-5.
- 107 Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, Merello M, Leiguarda R. Depression in classic versus akinetic-rigid Parkinson’s disease. Mov Disord 1989; 13: 29-33.
- 108 Stefanova N, Seppi K, Scherfler C, Puschban Z, Wenning GK. Depression in alphasynucleinopathies: prevalence, pathophysiology and treatment. J Neural Transm Suppl 2000; 60: 335-43.
- 109 Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 547.
- 110 Strang RR. Imipramine in Treatment of Parkinsonism:A Double-Blind Placebo Study. Br Med J 1965; 5452: 33-4.
- 111 Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 1996; 53: 175-9.
- 112 Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol 1997; 54: 625-30.
- 113 Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000; 15: 986-9.
- 114 Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988; 45: 497-501.
- 115 Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004; 52: 784-8.
- 116 Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 (Pt 4): 835-45.
- 117 Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58 (02) 160-6.
- 118 Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Ray Chaudhuri K, D’Olhaberriague L, Pearce RK. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184-9.